Scholar Rock (SRRK) Stock Price, News & Analysis

Company Overview

Scholar Rock Holding Corporation (NASDAQ: SRRK) is a clinical-stage biopharmaceutical company focused on developing medicines that selectively target the activation of growth factors. The company’s approach is designed to modulate biologic pathways in specific tissues while potentially limiting effects elsewhere in the body.

Scholar Rock’s lead product candidate is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin, a protein that negatively regulates muscle growth. The company is developing apitegromab for spinal muscular atrophy (SMA), a genetic neuromuscular disorder, and has evaluated the therapy in clinical studies involving patients with the disease. Its research has also included other growth-factor pathways and potential treatments for conditions involving muscle and tissue function.

Founded in 2012 and headquartered in Cambridge, Massachusetts, Scholar Rock conducts research and clinical development activities through collaborations and studies involving patients and medical centers in the United States and other countries. The company’s programs remain focused on advancing targeted biologic therapies rather than marketing a broad portfolio of commercial products. Jay Backstrom serves as president and chief executive officer.

Key Stats

• Today's Range: $40.52 to $41.83
• 50-Day Range: $40.52 to $60.04
• 52-Week Range: $27.07 to $61.76
• Volume: 1.10 million shs
• Average Volume: 2.39 million shs
• Market Capitalization: $4.93 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $67.67
• Consensus Rating: Moderate Buy

Scholar Rock Stock Analysis - MarketRank™

Scholar Rock scored higher than 62% of companies evaluated by MarketBeat, and ranked 343rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Scholar Rock has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 4 strong buy ratings, 10 buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

Scholar Rock has a consensus price target of $67.67, representing about 67.0% upside from its current price of $40.52.

Amount of Analyst Coverage

Scholar Rock has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Scholar Rock are expected to grow in the coming year, from ($3.23) to ($2.63) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Scholar Rock is -11.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scholar Rock is -11.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Scholar Rock has a P/B Ratio of 16.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.80% of the float of Scholar Rock has been sold short.

Short Interest Ratio / Days to Cover

Scholar Rock has a short interest ratio ("days to cover") of 9.32.

Change versus previous month

Short interest in Scholar Rock has recently increased by 17.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scholar Rock does not currently pay a dividend.

Dividend Growth

Scholar Rock does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.40

News Sentiment

Scholar Rock has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Scholar Rock this week, compared to 5 articles on an average week.

Search Interest

3 people have searched for SRRK on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

7 people have added Scholar Rock to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Scholar Rock insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.30% of the stock of Scholar Rock is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.08% of the stock of Scholar Rock is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SRRK
• CIK: 1727196
• Web: www.scholarrock.com
• Phone: (857) 259-3860
• Fax: 866-493-4935
• Employees: 289
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Scholar Rock: $67.67
• High Price Target: $84.00
• Low Price Target: $42.00
• Potential Upside/Downside: +67.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.94
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$377.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -160.19%
• Return on Assets: -87.18%

Debt

• Debt-to-Equity Ratio: 0.77
• Current Ratio: 7.02
• Quick Ratio: 7.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.41 per share
• Price / Book: 16.81

Miscellaneous

• Outstanding Shares: 121,790,000
• Free Float: 109,241,000
• Market Cap: $4.93 billion
• Optionable: Optionable
• Beta: 0.61